Thomas Illmer

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

Medicine, Genetics, Hematology +14

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)

Christian Thiede, Sina Koch, Eva Creutzig et al. · Blood · 2006 · 726 citations · Full text

Life Sciences, Genetics, Oncology +14

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 400 citations · Full text

Medicine, Hematology, Oncology +6